乳癌核心針活體組織切片 (CNB) 市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

Breast Cancer Core Needle Biopsy (CNB) Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月29日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球乳癌核心針切片市場價值為7.765億美元，由於乳癌發生率上升，導致早期診斷需求增加，預計2024年至2032年複合年成長率為7.8%。

世界衛生組織 (WHO) 報告稱，到 2022 年，全球約有 230 萬名女性被診斷出患有乳癌。女性對早期乳癌檢測的認知不斷提高，增加了對癌症篩檢計畫的需求，從而加大了對 CNB 等微創診斷程序的需求。

對癌症篩檢和診斷服務的需求極大地推動了乳癌核心針活體組織切片市場的發展。影像技術和乳房活體組織切片設備的創新正在提高 CNB 的準確性和安全性，促進其在已開發市場和新興市場的採用。

整個乳癌核心針活體組織切片產業根據影像引導技術、最終用戶和地區進行分類。

超音波引導細分市場佔據主導地位，預計在預測期內複合年成長率為 7.6%。它的突出源於其準確性和非侵入性方法。該技術利用即時超音波成像，精確定位可疑的乳房組織，確保從確切的關注區域採集活體組織切片樣本。優點包括縮短手術時間、最小化患者不適以及立即實現活體組織切片部位可視化。其成本效益和與臨床實踐的無縫整合進一步鞏固了其在乳癌核心針活體組織切片（CNB）市場的領先地位。

2023年，醫院佔據最大的市場佔有率，達到48.4%。他們的主導地位植根於廣泛的診斷能力和最先進的設施。醫院提供從超音波到乳房X光檢查等一系列影像技術以及活體組織切片程序，確保提高準確性和患者護理。他們有能力處理複雜的病例，並得到專業醫療團隊和全面後續護理的支持，豐富了診斷之旅。大量患者和強大的基礎設施推動了這些診斷程序在醫院的廣泛採用。

由於乳癌發生率高以及對有效診斷解決方案的需求不斷成長，2023年美國乳癌CNB市場價值為3.203億美元。美國癌症協會指出，大約八分之一的女性（約占美國女性人口的 13%）將在一生中面臨乳癌診斷。預計到 2024 年，乳癌將佔女性新診斷癌症的近 30%。這項統計數據凸顯了對高效診斷工具和程序的迫切需求。活體組織切片設備的持續技術進步和支持性報銷政策支撐了市場的成長軌跡。

產業生態系統分析
產業影響力
- 成長動力
  - 乳癌盛行率上升
  - 乳癌診斷技術的技術進步
  - 提高早期診斷意識
  - 擴大研發
- 產業陷阱與挑戰
  - 對替代診斷方法的偏好
  - 嚴格的監管要求
成長潛力分析
監管環境
技術景觀
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按影像引導技術，2021 - 2032 年

主要趨勢
立體定位引導
超音波引導
磁振造影 (MRI) 引導

第 6 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
癌症研究中心
診斷中心
研究和學術

第 7 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 8 章：公司簡介

Aurora Imaging Technology Inc.
BD
Devicor Medical Products, Inc.
Fujifilm Holdings
Hologic, Inc.
Insight Medbotics
McLaren
Rye Radiology
Siemens Healthcare Private Limited
Sentinelle Medical Inc.
Tampa General

簡介目錄

Product Code: 11100

The Global Breast Cancer Core Needle Biopsy Market was valued at USD 776.5 million in 2023 and is projected to expand at a CAGR of 7.8% from 2024 to 2032, driven by the rising incidence of breast cancer, leading to heightened demand for early diagnosis.

The World Health Organization (WHO) reported that around 2.3 million women were diagnosed with breast cancer worldwide in 2022. This trend has spurred the adoption of various biopsy techniques, notably Core Needle Biopsy (CNB). Growing awareness among women about early breast cancer detection has increased demand for cancer screening programs, intensifying the need for minimally invasive diagnostic procedures like CNB.

The demand for cancer screening and diagnostic services has significantly propelled the market for breast cancer core needle biopsies. Innovations in imaging technologies and breast biopsy devices are enhancing the accuracy and safety of CNB, boosting its adoption in both developed and emerging markets.

The overall breast cancer core needle biopsy industry is classified based on image-guided technology, end-user, and region.

The ultrasound-guided segment dominates the market and is projected to grow at a CAGR of 7.6% during the forecast period. Its prominence stems from its accuracy and non-invasive approach. Utilizing real-time ultrasound imaging, this technique precisely targets suspicious breast tissue, ensuring biopsy samples are taken from the exact area of concern. Benefits include reduced procedure time, minimal patient discomfort, and immediate biopsy site visualization. Its cost-effectiveness and seamless integration into clinical practices further cement its leading position in the breast cancer core needle biopsy (CNB) market.

In 2023, hospitals commanded the largest market share at 48.4%. Their dominance is rooted in extensive diagnostic capabilities and state-of-the-art facilities. Offering a suite of imaging technologies, from ultrasound to mammography, alongside biopsy procedures, hospitals ensure heightened accuracy and patient care. Their ability to manage intricate cases, backed by specialized medical teams and comprehensive follow-up care, enriches the diagnostic journey. High patient volumes and robust infrastructure drive the widespread adoption of these diagnostic procedures in hospitals.

In 2023, the U.S. breast cancer CNB market was valued at USD 320.3 million, due to a high breast cancer incidence and a growing demand for effective diagnostic solutions. The American Cancer Society notes that roughly 1 in 8 women, or about 13% of the U.S. female population, will face a breast cancer diagnosis in their lifetime. Projections for 2024 suggest breast cancer will represent nearly 30% of all new cancer diagnoses among females. This statistic highlights the urgent need for efficient diagnostic tools and procedures. Ongoing technological advancements in biopsy devices and supportive reimbursement policies bolster the market's growth trajectory.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of breast cancer
  - 3.2.1.2 Technological advancements in breast cancer diagnostics techniques
  - 3.2.1.3 Rising awareness for early diagnosis
  - 3.2.1.4 Expansion of research and development
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Preference for alternative diagnostic methods
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Image-guidance Technology, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Stereotactic-guided
5.3 Ultrasound-guided
5.4 Magnetic resonance imaging (MRI)-guided

Chapter 6 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospitals
6.3 Cancer research centers
6.4 Diagnostic centers
6.5 Research and academics

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa